Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HIV-1-specific RNA interference.

Daniel Boden1, Oliver Pusch, Bharat Ramratnam

  • 1Brown Medical School, Laboratory of Retrovirology, Division of Infectious Diseases, Department of Medicine, Providence, RI 02903, USA.

Current Opinion in Molecular Therapeutics
|October 8, 2004
PubMed
Summary

RNA interference (RNAi) shows promise as a novel therapy for HIV-1 infection by degrading viral RNA. Challenges remain in translating this gene-silencing technique into a durable antiviral treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of alendronate on survival and bone properties in Nothobranchius furzeri: insights from a model of accelerated aging.

Experimental gerontology·2026
Same author

Aging Reduces Intestinal Stem Cell Activity in Killifish and Intermittent Fasting Reverses Intestinal Gene Expression Patterns.

Aging cell·2025
Same author

Correction for Raines et al., "Nanoparticle delivery of Tat synergizes with classical latency reversal agents to express HIV antigen targets".

Antimicrobial agents and chemotherapy·2025
Same author

Cancer-associated fibroblasts shape early myeloid cell response to chemotherapy-induced immunogenic signals in next generation tumor organoid cultures.

Journal for immunotherapy of cancer·2024
Same author

Adeno-Associated Virus (AAV)-Delivered Exosomal TAT and BiTE Molecule CD4-αCD3 Facilitate the Elimination of CD4 T Cells Harboring Latent HIV-1.

Microorganisms·2024
Same author

Correction for Van Gulck et al., "A truncated HIV Tat demonstrates potent and specific latency reversal activity".

Antimicrobial agents and chemotherapy·2024

Area of Science:

  • Molecular Biology
  • Virology
  • Gene Therapy

Background:

  • RNA interference (RNAi) is a biological process involving sequence-specific RNA degradation.
  • Short-interfering RNA (siRNA) triggers RNAi, offering a tool for gene function studies.
  • Advances in vector design enable siRNA expression in human cells via short hairpin RNA (shRNA) cassettes.

Purpose of the Study:

  • To review the preclinical development of RNAi as a potential therapeutic agent for Human Immunodeficiency Virus type 1 (HIV-1) infection.
  • To explore the efficacy of RNAi in reducing HIV-1 replication in lymphocytic cells.
  • To identify challenges and recent research in converting RNAi into an antiviral therapy.

Main Methods:

  • Utilizing siRNA targeting viral proteins (Tat, Gag, Rev) and host factors (CCR5, CD4).
  • Employing short hairpin RNA (shRNA) expression cassettes for siRNA delivery.
  • Reviewing recent investigations on cellular delivery, antiviral durability, and gene-silencing specificity.

Main Results:

  • RNAi demonstrated the ability to decrease HIV-1 replication in lymphocytic cells.
  • siRNA targeting both viral and host factors proved effective in reducing viral load.
  • Research indicates potential for RNAi as a genetic therapy approach.

Conclusions:

  • RNAi is a powerful tool with potential for HIV-1 gene therapy.
  • Significant challenges exist in cellular delivery, durability, and specificity for therapeutic application.
  • Further research is needed to overcome obstacles for clinical translation.

Related Experiment Videos